<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9206090</journal-id>
<journal-id journal-id-type="pubmed-jr-id">2125</journal-id>
<journal-id journal-id-type="nlm-ta">J Intellect Disabil Res</journal-id>
<journal-id journal-id-type="iso-abbrev">J Intellect Disabil Res</journal-id>
<journal-title-group>
<journal-title>Journal of intellectual disability research : JIDR</journal-title>
</journal-title-group>
<issn pub-type="ppub">0964-2633</issn>
<issn pub-type="epub">1365-2788</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29034517</article-id>
<article-id pub-id-type="pmc">6188642</article-id>
<article-id pub-id-type="doi">10.1111/jir.12433</article-id>
<article-id pub-id-type="manuscript">NIHMS910736</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Medication Use by Adolescents and Adults with Fragile X Syndrome</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Laxman</surname>
<given-names>D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>DaWalt</surname>
<given-names>L. S.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Aman</surname>
<given-names>M. G.</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Greenberg</surname>
<given-names>J. S.</given-names>
</name>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Hong</surname>
<given-names>J.</given-names>
</name>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mailick</surname>
<given-names>M.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Department of Human Development and Family Studies, Utah State University, Logan, UT, USA</aff>
<aff id="A2">
<label>2</label>Waisman Center, University of Wisconsin-Madison, Madison, WI, USA</aff>
<aff id="A3">
<label>3</label>The Nisonger Center, The Ohio State University, Columbus, OH, USA</aff>
<aff id="A4">
<label>4</label>Waisman Center, University of Wisconsin, Madison, WI, USA</aff>
<aff id="A5">
<label>5</label>Waisman Center, University of Wisconsin, Madison, WI, USA</aff>
<author-notes>
<corresp id="FN1"><bold>Corresponding author:</bold> Dr. Daniel Laxman, Family, Consumer, and Human Development, Utah State University, 2705 Old Main Hill Logan, Utah, United States 84322-1400, <email>Dan.J.Laxman@gmail.com</email></corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>14</day>
<month>6</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="epub">
<day>15</day>
<month>10</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="ppub">
<month>2</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>2</month>
<year>2019</year>
</pub-date>
<volume>62</volume>
<issue>2</issue>
<fpage>94</fpage>
<lpage>105</lpage>
<!--elocation-id from pubmed: 10.1111/jir.12433-->
<abstract>
<sec id="S1">
<title>Background</title>
<p id="P1">The behavioural challenges and medical conditions associated with fragile X syndrome (FXS) can lead to increased need for medications.</p>
</sec>
<sec id="S2">
<title>Method</title>
<p id="P2">This longitudinal study examined the use of prescription medications for psychotropic and non-psychotropic purposes by adolescents and adults with FXS drawn from a North American community sample (<italic>N</italic> = 105). Odds and probabilities of continuing or discontinuing medication were calculated. Predictors of medication use were calculated.</p>
</sec>
<sec id="S3">
<title>Results</title>
<p id="P3">More than two-thirds took psychotropic medication, and about one-quarter took non-psychotropic medication. Over a three-year period, those who initially took prescription medications were considerably more likely to remain on medications than to stop. Individuals with more autism symptoms, more behavioural problems, a mental health diagnosis, and greater family income were significantly more likely to use psychotropic medication three years later. Individuals who had more health problems, a mental health diagnosis, and were female were more likely to use non-psychotropic medication over this time period.</p>
</sec>
<sec id="S4">
<title>Conclusions</title>
<p id="P4">Findings highlight the elevated and ongoing use of medication by individuals with FXS. Implications for social and behavioural research on FXS are discussed.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Fragile X syndrome</kwd>
<kwd>psychotropic medication</kwd>
<kwd>non-psychotropic medication</kwd>
<kwd>adolescents and adults</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>